Intended Audience
This activity was developed for diabetologists, internists, endocrinologists, nurses, and allied healthcare professionals
Statement of Need
The presence of overweight or obesity in individuals increases the risk of cardiovascular disease and diabetes. Studies demonstrate that weight loss, reduction in glycosylated hemoglobin (A1C) levels, and management of cardiovascular risk factors (dyslipidemia and hypertension) of diabetes are critical elements in reducing overall morbidity and mortality. This activity highlights the importance of intensive risk factor management for patients with diabetes, as reflected in the national guidelines for obesity (NHLBI), cholesterol (NCEP-ATP III), hypertension (JNC VII), and diabetes (ADA). Optimum management of diabetes depends on a comprehensive approach to treatment by healthcare providers. Because PCCs are first to treat and educate patients with diabetes, it is important that they are aware of evolving treatment options for diabetes to improve patient outcomes. This program will highlight the importance of PCCs as the first line of care in managing dysmetabolic risk factors and type 2 diabetes and their role in effective patient education and follow-up to improve treatment outcomes.
Learning Objectives
Accreditation and Certification
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and CogniMed Inc. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
There is no charge for this activity. Statements of Credit will be provided by mail following activity participation and upon completion and electronic submission of the posttest and evaluation form to CogniMed Inc. A link to the evaluation form is available upon completion of the activity or at http://www.primaryperspective.org/injecting_insight. Please allow 4 to 6 weeks for the delivery of your statement.
Faculty
| Frank Svec, MD, PhD Chairperson Clinical Professor of Medicine Tulane University Health Sciences Center New Orleans, Louisiana |
Catherine L. Martin, MS, APRN, BC-ADM, CDE Clinical Study Coordinator Division of Metabolism, Endocrinology, and Diabetes University of Michigan Health System Ann Arbor, Michigan |
| Robert S. Busch, MD Clinical Endocrinologist Albany, New York |
Anne L. Peters, MD, FACP, CDE Director of Clinical Diabetes Programs Professor of Clinical Medicine Keck School of Medicine University of Southern California Los Angeles, California |
Disclosure Declaration
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored activities are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed.
In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:
Annenberg Center for Health Sciences
All staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.
CogniMed Inc.
All staff at CogniMed Inc. have nothing to disclose.
Frank Svec, MD, PhD
Dr Svec serves on the speakers bureau of Novartis.
Robert S. Busch, MD
Dr Busch has nothing to disclose.
Catherine L. Martin, MS, APRN, BC-ADM, CDE
Ms Martin serves on the speakers bureaus and advisory boards of Amylin Pharmaceuticals, Inc., and Eli Lilly and Company.
Anne L. Peters, MD, FACP, CDE
Dr Peters is a consultant for and serves on the speakers bureaus of Abbott Diabetes Care; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Medtronic MiniMed; Novo Nordisk; and Takeda Pharmaceuticals.
The faculty have disclosed that there will be discussion about the use of products for non–FDA-approved indications.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
This activity is supported by an independent educational grant provided by
This activity is an enduring material and consists of a Web posting. Successful completion is achieved by viewing the material, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete this activity is 1 hour.
This activity was originally released December 11, 2009, and is eligible for credit through December 11, 2010.